Biohaven Ltd. 8-K

What Happened
Biohaven Ltd. announced positive clinical results across multiple programs and presented them at its R&D Day. In a May 26, 2026 press release the company reported new clinical data for opakalim, a selective Kv7.2/7.3 activator, highlighting seizure control and a differentiated tolerability profile in epilepsy. In a May 27, 2026 press release Biohaven reported positive clinical biomarker and patient data for its first MoDE and TRAP extracellular protein degraders, showing deep, rapid, selective lowering of disease‑driving antibodies in Graves' disease and IgA nephropathy. The company also made a presentation at its annual R&D Day held with the Yale Innovation Summit on May 27, 2026. These items were furnished as exhibits to the 8‑K (Exhibits 99.1–99.3) and are described as furnished, not filed, under the Exchange Act.

Key Details

• Press releases: May 26, 2026 (opakalim in epilepsy) and May 27, 2026 (MoDE/TRAP degraders in Graves' disease and IgA nephropathy).
• Programs cited: opakalim (selective Kv7.2/7.3 activator) and first MoDE/TRAP extracellular protein degraders.
• Presentation: Investor/R&D Day presentation delivered May 27, 2026 at the Yale Innovation Summit; presentation attached as Exhibit 99.3 to the 8‑K.
• Disclosure status: Information furnished on Form 8‑K and expressly stated as not “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters
Positive clinical and biomarker results can de‑risk Biohaven’s pipeline and influence investor perceptions of program value and development prospects. The opakalim data address both efficacy (seizure control) and tolerability, key factors for epilepsy therapeutics. The MoDE/TRAP degrader data signal potential proof of concept for a novel extracellular degrader approach in autoimmune kidney and thyroid disease. Investors should review the full press releases and the R&D Day presentation (Exhibits 99.1–99.3) for detailed data; note that the company characterized these materials as furnished, not filed.